{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T09:09:06Z","timestamp":1788944946568,"version":"build-2803163510"},"reference-count":27,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: The optimal treatment strategy for older patients with acute myeloid leukemia (AML) remains uncertain because treatment selection is influenced by age, comorbidity, functional status, and disease biology. This study explored real-world outcomes with intensive and non-intensive treatment strategies. Materials and Methods: We retrospectively analyzed 69 patients aged \u2265 65 years diagnosed with AML between 2012 and 2022 at a tertiary center. Treatment intensity was defined by regimen. Baseline demographic, clinical, and laboratory parameters were recorded. Progression-free survival (PFS) and overall survival (OS) were estimated by the Kaplan\u2013Meier method and compared using log-rank tests. Results: A total of 69 patients were included, with a median age of 71 years. Intensive and non-intensive therapies were administered in 24.2% and 75.8% of treated patients, respectively. The median PFS was 6.7 months, and the median OS was 7.8 months. One- and two-year OS rates were 29% and 9.2%, respectively. No significant differences in PFS or OS were observed between treatment intensity groups. Among response-evaluable patients, complete remission\/complete remission with incomplete hematologic recovery (CR\/CRi) was achieved in 58.0% of intensively treated patients and 43.3% of those receiving hypomethylating agent (HMA)-based therapy. Among the evaluated baseline variables, only Eastern Cooperative Oncology Group (ECOG) performance status was significantly associated with overall survival. Patients with an ECOG performance status \u2265 2 had significantly shorter OS than those with ECOG &lt;2 (median OS: 4.85 vs. 8.60 months, p = 0.009). Conclusions: In this real-world cohort of older patients with AML, no statistically significant differences in PFS or OS were observed between intensive and non-intensive treatment strategies. Although CR\/CRi rates were numerically higher with intensive therapy, disease progression remained frequent among patients who achieved a response. ECOG performance status was significantly associated with overall survival, highlighting the relevance of functional status in individualized treatment selection. These findings should not be interpreted as evidence of therapeutic equivalence.<\/jats:p>","DOI":"10.3390\/medicina62091733","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:05:43Z","timestamp":1788941143000},"page":"1733","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intensive Versus Non-Intensive Therapy in Older Patients with Acute Myeloid Leukemia: A Real-World Experience"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8788-8222","authenticated-orcid":false,"given":"Dila Elifsu","family":"Yuksekli","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Institute of Oncology, Istanbul University, 34093 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4586-3809","authenticated-orcid":false,"given":"Arda","family":"Bayar","sequence":"additional","affiliation":[{"name":"Department of Hematology, Marmara University Pendik Training and Research Hospital, 34854 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"formal-analysis","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5544-1880","authenticated-orcid":false,"given":"Ceren","family":"Uzunoglu Guren","sequence":"additional","affiliation":[{"name":"Department of Hematology, Marmara University Pendik Training and Research Hospital, 34854 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"}]},{"given":"Fatma","family":"Arikan","sequence":"additional","affiliation":[{"name":"Department of Hematology, Marmara University Pendik Training and Research Hospital, 34854 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8102-8627","authenticated-orcid":false,"given":"Fatma","family":"Temiz","sequence":"additional","affiliation":[{"name":"Department of Hematology, Marmara University Pendik Training and Research Hospital, 34854 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-0149","authenticated-orcid":false,"given":"Ahmet Mert","family":"Yanik","sequence":"additional","affiliation":[{"name":"Department of Hematology, University of Health Sciences, Bursa City Training and Research Hospital, 16110 Bursa, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2690-8581","authenticated-orcid":false,"given":"Tayfur","family":"Toptas","sequence":"additional","affiliation":[{"name":"Department of Hematology, Marmara University Pendik Training and Research Hospital, 34854 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7876-6896","authenticated-orcid":false,"given":"Isik","family":"Kaygusuz Atagunduz","sequence":"additional","affiliation":[{"name":"Department of Hematology, Marmara University Pendik Training and Research Hospital, 34854 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"project-administration","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]},{"given":"Tulin","family":"Tuglular","sequence":"additional","affiliation":[{"name":"Department of Hematology, Acibadem Hospital, 34718 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"resources","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]},{"given":"Asu Fergun","family":"Yilmaz","sequence":"additional","affiliation":[{"name":"Department of Hematology, Marmara University Pendik Training and Research Hospital, 34854 Istanbul, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"ref_1","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"106339","DOI":"10.1016\/j.leukres.2020.106339","article-title":"Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia","volume":"91","author":"Griffiths","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1182\/blood.V89.9.3323","article-title":"Acute myeloid leukemia in the elderly: Assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study","volume":"89","author":"Leith","year":"1997","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/bjh.12750","article-title":"Prognostic factors for acute myeloid leukaemia in adults: Biological significance and clinical use","volume":"165","author":"Liersch","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1182\/blood-2023-191110","article-title":"Methods of Estimating Renal Function for Use in Clinical Trial Eligibility Criteria Widely Vary in Phase II and III Clinical Trials in Acute Myeloid Leukemia","volume":"142","author":"Pullarkat","year":"2023","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1200\/JCO.21.00960","article-title":"When less is more: Reevaluating the role of intensive chemotherapy for older adults with acute myeloid leukemia in the modern era","volume":"39","author":"Short","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11912-020-00964-1","article-title":"Management of acute myeloid leukemia (AML) in older patients","volume":"22","author":"Abdallah","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1182\/blood.2020008812","article-title":"Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia","volume":"138","author":"Sorror","year":"2021","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.leukres.2018.10.011","article-title":"Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience","volume":"75","author":"Vachhani","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1182\/bloodadvances.2025017934","article-title":"American Society of Hematology 2025 guidelines for treating newly diagnosed acute myeloid leukemia in older adults","volume":"10","author":"Sekeres","year":"2026","journal-title":"Blood Adv."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4422","DOI":"10.1182\/blood-2010-03-276485","article-title":"Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia","volume":"116","author":"Kantarjian","year":"2010","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1007\/s00277-014-2126-9","article-title":"Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: Results from the Austrian Azacitidine Registry of the AGMT-Study Group","volume":"93","author":"Pleyer","year":"2014","journal-title":"Ann. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1002\/cncr.21723","article-title":"Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: Predictive prognostic models for outcome","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41375-021-01425-9","article-title":"Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: A large patient data set study from European registries","volume":"36","author":"Bertoli","year":"2022","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Wei","year":"2022","journal-title":"Blood"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/ajh.25162","article-title":"Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience","volume":"93","author":"Ganzel","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: A systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/blood.2021013626","article-title":"2021 update on MRD in acute myeloid leukemia: A consensus document from the European LeukemiaNet MRD Working Party","volume":"138","author":"Heuser","year":"2021","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Ferrara, F., Lessi, F., Vitagliano, O., Borlenghi, E., and Rossi, G. (2019). Current therapeutic results and treatment options for older patients with relapsed acute myeloid leukemia. Cancers, 11.","DOI":"10.3390\/cancers11020224"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4840","DOI":"10.1182\/blood-2012-06-436055","article-title":"Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia","volume":"120","author":"Ravandi","year":"2012","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Chang, Y., Guyatt, G.H., Teich, T., Dawdy, J.L., Shahid, S., Altman, J.K., Stone, R.M., Sekeres, M.A., Mukherjee, S., and LeBlanc, T.W. (2021). Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0249087"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Karakus, V., Pinar, I.E., Iltar, U., Yenihayat, E.M., Polat, M.G., Celik, S., Malkan, U.Y., Seval, G.C., Dogan, A., and Akdeniz, A. (2025). Clinical characteristics, treatment approaches, and survival predictors in adult acute myeloid leukemia: Interim results from the Turkish Society of Hematology AML Registry. J. Clin. Med., 14.","DOI":"10.3390\/jcm14207367"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41375-022-01745-4","article-title":"Effect of ECOG performance status on outcomes in patients with acute myeloid leukemia and other high-grade myeloid neoplasms","volume":"37","author":"Paras","year":"2023","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Hao, Q., Foroutan, F., Han, M.A., Devji, T., Nampo, F.K., Mukherjee, S., Rosko, A., Sekeres, M.A., Guyatt, G.H., and Brignardello-Petersen, R. (2022). Prognosis of older patients with newly diagnosed AML undergoing antileukemic therapy: A systematic review. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0278578"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Dumitru, I.G., Todor, S.B., Ichim, C., Helgiu, C., and Helgiu, A. (2025). A literature review on the impact of the gut microbiome on cancer treatment efficacy, disease evolution and toxicity: The implications for hematological malignancies. J. Clin. Med., 14.","DOI":"10.3390\/jcm14092982"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/9\/1733\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T08:45:27Z","timestamp":1788943527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/9\/1733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":27,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["medicina62091733"],"URL":"https:\/\/doi.org\/10.3390\/medicina62091733","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]}}}